Posts tagged ‘ASCO’
April 15th, 2011
In order to understand the mechanism of action (MOA) of a drug, you first have to know the underlying biology of the disease. This is particularly important for new products, where you are often analyzing how you compare to competitors, and the strengths and weaknesses each may have in their MOA.
In anticipation of new data at the forthcoming American Society of Clinical Oncology (ASCO) meeting, Sally Church on Pharma Strategy Blog provides a review of two hematologic malignancies, indolent B-cell lymphoma and chronic lymphocytic leukemia (CLL).
In Sally’s post, she applies what we know about the underlying science to current drug therapies. One of her conclusions is that FCR (fludarabine, cyclophosphamide, rituximab) “is now very much the bedrock of treatment for patients with CLL and is based on a very solid rationale.”
For those interested in what new therapies are emerging for CLL, you’ll have to read further on Pharma Strategy Blog.
Sally is a regular attendee at the annual meetings of the American Society of Hematology (ASH) and ASCO, and has particular expertise in this area. Please feel free to contact us to find out how we can help you bring new hematology products to market.
April 1st, 2011
We are excited to hear that Sally Church has produced another video to follow on from her recent video debut on Pharma Strategy Blog.
Produced by the aptly named, “PSB Films”, it is a trailer for her eagerly awaited post on “What’s hot at AACR 2011?”
Readers of Sally’s blog will know that prior to major scientific meetings such as AACR, ASCO and ASH, Sally often provides a mixture of commentary and insight on what she predicts will be hot topics.
Happy April 1st!
February 15th, 2011
It’s that time of year, when the prospect of an escape from New Jersey to Florida for some sunshine is quite appealing to all in the pharma industry.
ASCO Genitourinary (GU) 2011 starts this week in Orlando, and Sally Church from Icarus Consultants will be at the meeting.
From the number of flyers for educational symposia we’ve received, prostate cancer looks to be a hot topic, and some new data appears likely.
If you are attending, do say hello to Sally or invite her for a coffee (or something stronger).
December 22nd, 2010
Published by Pieter Droppert on Biotech Strategy Blog